24H|Abivax Shares Surged 22% As To Attract Interest From Eli Lilly
Abivax Shares Surged 22% As To Attract Interest From Eli Lilly

According to a story in the French-language newspaper La Tribune on December 24, 2025, there have been rumors that Eli Lilly has been drawing interest in the French biotechnology business ABIVAX Société Anonyme (NASDAQ:ABVX), TheFly reported.
Thefly revealed on December 18, 2025, that Guggenheim analyst Yatin Suneja has increased the company’s price objective for ABIVAX Société Anonyme (NASDAQ:ABVX) from $150 to $175. The analyst maintained a Buy rating for the stock. Guggenheim’s positive forecast for obefazimod ahead of an impending 44-week maintenance readout is the basis for the price target hike.
The firm has €589.7 million in cash despite high R&D-driven losses and a €15.3 million monthly cash burn.
Recommended Articles










Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.